Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters

Objectives:To identify factors associated with sustained undetectable viraemia after HIV-1 seroconversion in treatment-naive patients, and to describe concomitant CD4 cell count progression. Methods:Seroconverters enrolled in CASCADE were assumed to control viraemia if at least two consecutive viral load measurements were < 400/500 copies/ml without treatment. Factors associated with undetectable viraemia were identified through a logistic regression. A joint model was used to describe simultaneously the CD4 cell count progression during and after that period and to identify factors associated with sustained undetectable viraemia. Results:Of 2176 seroconverters, 145 (6.7%) spontaneously controlled viraemia. Women were more likely than men to achieve undetectable viraemia [adjusted odds ratio (OR), 2.12; 95% confidence interval (CI), 1.49–3.12] unlike patients who reported a symptomatic primary infection (adjusted OR, 0.58; 95% CI, 0.36–0.94). AIDS and death rates were significantly lower in patients achieving undetectable viraemia than in the others. The median period of undetectable viraemia was 11.2 months; on average, CD4 cell counts remained stable during that period, and decreased with a mean rate of 5 cells/μl per month thereafter. High CD4 cell count at the beginning of undetectable viraemia and non-symptomatic primary infection favoured the preservation of undetectable viraemia. Conclusion:A small proportion of seroconverters appeared to be able to control HIV viraemia spontaneously, mostly those without seroconversion illness and within a few years following seroconversion; this is associated with the benefits of slower CD4 cell count decline and improved long-term prognosis. Such persons should be targeted for in depth investigation.

[1]  C. Rouzioux,et al.  HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  C. Rouzioux,et al.  Undetectable viremia without antiretroviral therapy in patients with HIV seroconversion: an uncommon phenomenon? , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  N. Hessol,et al.  Sex and the course of HIV infection in the pre- and highly active antiretroviral therapy eras , 2005, AIDS.

[4]  D. Hawkins,et al.  Do patients who are infected with drug-resistant HIV have a different CD4 cell decline after seroconversion? An exploratory analysis in the UK Register of HIV Seroconverters , 2004, AIDS.

[5]  Bradley P Carlin,et al.  Separate and Joint Modeling of Longitudinal and Event Time Data Using Standard Computer Packages , 2004 .

[6]  J. Gentle,et al.  Special Section: Teaching Computational Statistics , 2004 .

[7]  S J Pocock,et al.  A comparison of two methods for the estimation of precision with incomplete longitudinal data, jointly modelled with a time‐to‐event outcome , 2003, Statistics in medicine.

[8]  A. Mocroft,et al.  Decline in the AIDS and death rates in the EuroSIDA study: an observational study , 2003, The Lancet.

[9]  C. Sabin,et al.  Short-term CD4 cell response after highly active antiretroviral therapy initiated at different times from seroconversion in 1,500 seroconverters. , 2003, Journal of acquired immune deficiency syndromes.

[10]  Cascade Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE. , 2000 .

[11]  M. Prins,et al.  Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE , 2000, HIV medicine.

[12]  Hiv Survival,et al.  Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis , 2000, The Lancet.

[13]  C. Rouzioux,et al.  Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection , 2000, AIDS.

[14]  F. Roudot-thoraval,et al.  Plasma human immunodeficiency virus RNA below 40 Copies/mL is rare in untreated persons even in the first years of infection. , 1999, The Journal of infectious diseases.

[15]  M. Plana,et al.  Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. , 1999, AIDS.

[16]  P. Harrigan,et al.  Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. , 1999, AIDS.

[17]  M. Kazatchkine,et al.  Gender differences in CD4+ cell counts persist after HIV‐1 infection , 1997 .

[18]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[19]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.